Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 05PRAGUE147, CZECH GOVERNMENT TAKES NOTICE OF WARNINGS ON

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #05PRAGUE147.
Reference ID Created Released Classification Origin
05PRAGUE147 2005-02-02 07:41 2011-08-25 00:00 UNCLASSIFIED Embassy Prague
This record is a partial extract of the original cable. The full text of the original cable is not available.
UNCLAS SECTION 01 OF 02 PRAGUE 000147 
 
SIPDIS 
 
STATE FOR EUR/NCE AND EB/TPP/MTA/IPC 
COMMERCE FOR 4232/ITA/MAC/MROGERS 
STATE PASS USTR FOR LERRION 
 
E.O. 12958: N/A 
TAGS: ETRD KIPR EZ USTR
SUBJECT: CZECH GOVERNMENT TAKES NOTICE OF WARNINGS ON 
PHARMACEUTICAL MARKET ACCESS 
 
REF: PRAGUE 76 
 
1.  Summary: U.S. pharmaceutical companies' concerns about 
obstacles to market access in the Czech Republic will be 
raised in their 2005 Special 301 submission.  Embassy Prague 
has raised with the GOCR the pharma industry's complaints 
about the discriminatory effect of Ministry of Health setting 
of reimbursement levels for the national health insurance and 
Ministry of Finance setting of maximum prices, as well as 
other practices that tend to restrict market access.  The 
pharmaceutical industry's complaints are now beginning to get 
attention from the GOCR.  The Ministry of Health is preparing 
new rules for determining reimbursement with the input of the 
pharma companies, although it remains to be seen if the 
result will be helpful or not.  The right to appeal the 
Ministry of Health's reimbursement decrees remains unclear. 
Our contact at the Ministry of Health has promised to review 
specific claims of discrimination.  Similarly, the Ministry 
of Foreign Affairs has promised to study the impact of the 
Ministry of Finance maximum price decrees.  End Summary. 
 
2.  The Embassy has followed up the Ambassador's letter and 
meeting with the Ministry of Trade and Industry reported 
reftel with meetings with the Ministry of Health and Ministry 
of Foreign Affairs.  The intent of these meetings is to use 
the leverage provided by the Special 301 process to ensure 
that the relevant Czech officials take notice of the U.S. 
pharmaceutical industry's concerns and begin to take action 
to address them. 
 
HEALTH MINISTRY WORKING ON NEW REIMBURSEMENT SYSTEM 
--------------------------------------------- ------ 
 
3.  On January 24, we met with Katarina Bartikova, head of 
the Pharmacy Department of the Ministry of Health.  As such, 
she is the official in charge of the process of setting 
reimbursement levels for the national health insurance 
system.  Bartikova has been in her job since December, 
although she worked for the Pharmacy Department prior to a 
hiatus during which, she said, she was working for an 
American pharmaceutical company that she refused to name. 
Bartikova said she is determined to bring more transparency 
to the reimbursement process.  She is preparing a new process 
for determining reimbursement levels with what she terms 
clear standards.  Bartikova has met five or six times since 
December with MAFS (the International Association of 
Pharmaceutical Companies, the local association of U.S. and 
European pharma companies) to discuss what the standards 
should be. (Note: based on her prior work at the Ministry, 
local representatives of U.S. pharmaceutical companies view 
Bartikova as an adversary.  They are skeptical of her 
commitment to setting fair standards.) 
 
4.  The new standards for reimbursement mentioned by 
Bartikova are apparently still a work in progress.  The paper 
she showed us is relatively clear about the information that 
must be gathered by the Ministry, but it remains rather vague 
about the rules that will be applied to that information to 
reach a decision on a level of reimbursement. 
 
5.  Regarding the actual setting of reimbursement levels, we 
agreed that there will always be tension between the 
Ministry's desire to keep costs as low as possible and the 
pharma industry's desire that its products be reimbursed to 
the full extent possible.   Bartikova agreed as well that the 
industry should have an opportunity to argue that a 
particular patented product has such special properties that 
it belongs in a different therapeutic category than the 
generic, with a correspondingly different reimbursement, even 
if it treats the same disease.  One of the problems the U.S. 
industry has had heretofore has been getting a fair chance to 
make that argument. 
 
5.  With respect to claims that the system of reimbursement 
discriminates in favor of domestic products in the same 
therapeutic category as imported products, Bartikova said 
that each such case depends on the facts and asked us to 
provide particulars.  With the pharma companies' permission, 
we have shared with her the detailed statement of their 
concerns that will likely form the basis of their Special 301 
submission. 
 
6.  Although the pharma industry has long been critical of 
the "categorization committee" that advised the Minister of 
Health on reimbursement decisions, it was dismayed when 
Minister Emmerova's dismissed it last year because of its 
inattention to "social democratic values" in its work. 
Bartikova did not seem convinced of a need for such a 
committee in the first place and was not in a hurry to 
reconstitute it.  She said that the new standards should be 
in place before appointing a new committee can be considered. 
 She also linked the companies' right to appeal the 
Minister's final reimbursement decree to the establishment of 
standards.  She was unwilling to say whether or not she 
believed such decisions are appealable. 
 
MINISTRY OF FOREIGN AFFAIRS DEFENDS THE STATUS QUO 
--------------------------------------------- ----- 
 
7.  On January 27, we met with Jana Reinisova, Director of 
the Domestic Markets and Sectorial Policies unit of the 
European Union Department of the Ministry of Foreign Affairs. 
 Reinisova gave us a paper (cleared with other interested 
ministries) responding to concerns raised by USTR in a recent 
telephone conversation with the Czech Embassy in Washington. 
For the most part, the paper contains flat denials of the 
allegations as they were understood by the MFA from the Czech 
Embassy.  It also contains figures on the growth of public 
expenditure for drugs and on the growth of Czech expenditures 
for medicines produced by the U.S. company Eli Lilly. 
According to the Ministry, these expenditures have grown from 
Kc 556.6 million ($24.2 million) in 2001 to Kc 787.1 million 
($34.2 million) in 2003, with expenditures for the first half 
of 2004 already at Kc 475.8 million ($20.6 million). 
 
8. We discussed with Reinisova the current top concern of the 
pharmaceutical industry, which is a new decree of the 
Ministry of Finance that, according to a legal analysis 
commissioned by MAFS, subjects domestically-produced drugs to 
a simpler calculation of maximum price than imported drugs. 
The producer of imports must submit information on direct 
costs of material, direct salaries, other direct costs, 
indirect costs and profit.  The pharma companies contend that 
this formulation is disadvantageous to them.  Reinisova was 
not familiar with the new decree but promised to study it. 
 
SPECIAL 301 WILL PUT THE PROBLEM IN FOCUS 
----------------------------------------- 
 
9.  Comment: The Czech government has historically been 
sensitive to the possibility that it may be placed on the 
Special 301 watch list.  The Ambassador's letter (reftel) and 
the USTR inquiry to the Czech Embassy have already put the 
working levels of the Ministries of Health, Foreign Affairs 
and Trade and Industry on their mettle to defend the Czech 
system as it affects imported products.  A strong response 
from the GOCR to Phrma's formal Special 301 submission can be 
expected.  The industry's complaints seem to be influencing 
the Ministry of Health to attempt to create at least a veneer 
of transparency for the reimbursement process.  The 
involvement of MAFS in determining the standards is 
encouraging, but it remains to be seen whether the ultimate 
result will allow the pharmaceutical companies to get a 
handle on how reimbursement prices are actually set and 
create a basis for a reasoned appeal if necessary.  End 
Comment. 
 
CABANISS